# Phase 3 glomerulonephritis trials recruiting: 20 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 20 trials in phase 3 for glomerulonephritis that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 3 glomerulonephritis trials: 20 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-3/glomerulonephritis

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 20
- Recruiting or not yet: 20
- Read on: November 19, 2026

## Trials

The 20 newest of 20, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 29, 2026 | NCT07902817 | A Phase 3 Blinded Study of JADE101 in Participants With Immunoglobulin A Nephropathy | Jade Biosciences, Inc. | Phase 3 | Recruiting | IgA Nephropathy (IgAN) | 480 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07902817) |
| October 22, 2026 | NCT07890909 | A Phase 3b Study of Participant Experience on Povetacicept Administered Via Autoinjector as Compared to Sibeprenlimab Administered Via... | Vertex Pharmaceuticals Incorporated | Phase 3 | Recruiting | Immunoglobulin A Nephropathy | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07890909) |
| October 1, 2026 | NCT07851220 | A Phase 3 Study of Inebilizumab in Participants With Primary Membranous Nephropathy | Amgen | Phase 3 | Recruiting | Glomerulonephritis, Membranous | 159 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07851220) |
| September 30, 2026 | NCT07850752 | A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA Nephropathy | Novartis Pharmaceuticals | Phase 3 | Not yet recruiting | IgA Nephropathy (IgAN) | 340 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07850752) |
| August 18, 2026 | NCT07770815 | Trial of Sibeprenlimab in Children and Adolescents With Immunoglobulin A Nephropathy (IgAN) | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 3 | Not yet recruiting | IgA Nephropathy | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07770815) |
| June 11, 2026 | NCT07642050 | A Study to Determine if BHV-1400 is Effective and Safe in Adults With IgA Nephropathy | Biohaven Therapeutics Ltd. | Phase 3 | Not yet recruiting | IgA Nephropathy | 420 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07642050) |
| March 27, 2026 | NCT07498335 | Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN | Novartis Pharmaceuticals | Phase 3 | Recruiting | Berger Disease, Bergers Disease, IgA Nephropathy, Immunoglobulin A Nephropathy, Primary IgAN, Nephritis IgA Type... | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07498335) |
| February 5, 2026 | NCT07390123 | Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN | Haisco Pharmaceutical Group Co., Ltd. | Phase 3 | Recruiting | IgA Nephropathy (IgAN) | 370 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07390123) |
| July 8, 2025 | NCT07052981 | Clinical Study on the Efficacy and Safety of Telitacicept in the Treatment of Pediatric IgA Nephropathy or IgA Vasculitis Nephritis | Sponsor not shown (see the record) | Phase 3 | Not yet recruiting | IgA Nephropathy (IgAN), IgAVN | 124 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07052981) |
| June 17, 2025 | NCT07024563 | Study of Ravulizumab in Pediatric Participants With Primary IgAN | Alexion Pharmaceuticals, Inc. | Phase 3 | Recruiting | IgAN, IgAVN, Immunoglobulin A Nephropathy, Immunoglobulin A Vasculitis Associated Nephritis, Henoch-schonlein Purpura... | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07024563) |
| May 29, 2025 | NCT06994845 | Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN | Novartis Pharmaceuticals | Phase 3 | Recruiting | Primary Immunoglobulin A Nephropathy (IgAN) | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06994845) |
| April 20, 2025 | NCT06935357 | A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) | Biogen | Phase 3 | Recruiting | Immunoglobulin A Nephropathy (IgAN) | 454 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06935357) |
| March 5, 2025 | NCT06858319 | Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy. | Novartis Pharmaceuticals | Phase 3 | Recruiting | Kidney Diseases, Kidney Diseases, Chronic, Urological Diseases, Glomerulonephritis, Glomerular Disease... | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06858319) |
| February 11, 2025 | NCT06819826 | A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria | Biocity Biopharmaceutics Co., Ltd. | Phase 3 | Recruiting | IgA Nephropathy (IgAN) | 360 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06819826) |
| April 2, 2024 | NCT06341205 | Personalized Rituximab Treatment Based on Artificial Intelligence in Membranous Nephropathy (iRITUX) | Centre Hospitalier Universitaire de Nice | Phase 3 | Recruiting | Membranous Nephropathy | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06341205) |
| April 3, 2023 | NCT05795140 | Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS | Novartis Pharmaceuticals | Phase 3 | Recruiting | Atypical Hemolytic Uremic Syndrome | 65 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05795140) |
| August 22, 2022 | NCT05510323 | Efficacy of Immunosuppressive Therapy for IgA Nephropathy With Stage 3 or 4 CKD | Air Force Military Medical University, China | Phase 3 | Recruiting | Glomerulonephritis, IGA | 208 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05510323) |
| February 9, 2021 | NCT04745728 | Different Immunosuppressive Treatment in iMN | Peking Union Medical College Hospital | Phase 3 | Recruiting | Idiopathic Membranous Nephropathy | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04745728) |
| September 21, 2020 | NCT04557462 | A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With... | Novartis Pharmaceuticals | Phase 3 | Recruiting | Primary IgA Nephropathy | 540 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04557462) |
| May 20, 2019 | NCT03955445 | Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN | Novartis Pharmaceuticals | Phase 3 | Recruiting | C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis | 225 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03955445) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Novartis Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals) | 7 |
| [Vertex Pharmaceuticals Incorporated](https://specstream.ai/data/clinical-trials/company/vertex-pharmaceuticals-incorporated) | 1 |
| [Biohaven Therapeutics Ltd.](https://specstream.ai/data/clinical-trials/company/biohaven-therapeutics-ltd) | 1 |
| Air Force Military Medical University, China | 1 |
| [Haisco Pharmaceutical Group Co., Ltd.](https://specstream.ai/data/clinical-trials/company/haisco-pharmaceutical-group-co-ltd) | 1 |
| Jade Biosciences, Inc. | 1 |
| [Alexion Pharmaceuticals, Inc.](https://specstream.ai/data/clinical-trials/company/alexion-pharmaceuticals-inc) | 1 |
| [Biogen](https://specstream.ai/data/clinical-trials/company/biogen) | 1 |
| Biocity Biopharmaceutics Co., Ltd. | 1 |
| Centre Hospitalier Universitaire de Nice | 1 |
| [Otsuka Pharmaceutical Development & Commercialization, Inc.](https://specstream.ai/data/clinical-trials/company/otsuka-pharmaceutical-development-and-commercialization-inc) | 1 |
| Peking Union Medical College Hospital | 1 |
| [Amgen](https://specstream.ai/data/clinical-trials/company/amgen) | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 11 |
| United States | 10 |
| Japan | 7 |
| Spain | 6 |
| Argentina | 5 |
| Canada | 5 |
| France | 5 |
| South Korea | 5 |
| Taiwan | 5 |
| Australia | 4 |
| Brazil | 4 |
| Czechia | 4 |
| Germany | 4 |
| Italy | 4 |
| Turkey (Türkiye) | 4 |
| Colombia | 3 |
| India | 3 |
| Israel | 3 |
| Malaysia | 3 |
| United Kingdom | 3 |
| Belgium | 2 |
| Hong Kong | 2 |
| Mexico | 2 |
| Netherlands | 2 |
| Greece | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Dumpster rental companies in the United States](https://specstream.ai/data/businesses/dumpster-rental-companies/united-states)
- [Manufacturing consultants in the United States](https://specstream.ai/data/businesses/manufacturing-consultants/united-states)
- [Sports medicine clinics in the United States](https://specstream.ai/data/businesses/sports-medicine-clinics/united-states)
- [Blinds and shades companies in the United States](https://specstream.ai/data/businesses/blinds-and-shades-companies/united-states)
- [General hospitals in the United States](https://specstream.ai/data/businesses/general-hospitals/united-states)
- [Pediatric neurology practices in the United States](https://specstream.ai/data/businesses/pediatric-neurology-practices/united-states)
